- Home
- ILPT vs CTNM Comparison
ILPT vs CTNM Comparison
Compare ILPT & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILPT
- CTNM
- Stock Information
- Founded
- ILPT 2017
- CTNM 2009
- Country
- ILPT United States
- CTNM United States
- Employees
- ILPT N/A
- CTNM N/A
- Industry
- ILPT Real Estate Investment Trusts
- CTNM
- Sector
- ILPT Real Estate
- CTNM
- Exchange
- ILPT Nasdaq
- CTNM Nasdaq
- Market Cap
- ILPT 366.2M
- CTNM 328.1M
- IPO Year
- ILPT 2018
- CTNM 2024
- Fundamental
- Price
- ILPT $5.28
- CTNM $11.01
- Analyst Decision
- ILPT
- CTNM Strong Buy
- Analyst Count
- ILPT 0
- CTNM 5
- Target Price
- ILPT N/A
- CTNM $22.20
- AVG Volume (30 Days)
- ILPT 264.0K
- CTNM 92.7K
- Earning Date
- ILPT 10-28-2025
- CTNM 10-30-2025
- Dividend Yield
- ILPT 3.79%
- CTNM N/A
- EPS Growth
- ILPT N/A
- CTNM N/A
- EPS
- ILPT N/A
- CTNM N/A
- Revenue
- ILPT $445,459,000.00
- CTNM N/A
- Revenue This Year
- ILPT $3.44
- CTNM N/A
- Revenue Next Year
- ILPT $1.78
- CTNM N/A
- P/E Ratio
- ILPT N/A
- CTNM N/A
- Revenue Growth
- ILPT 1.08
- CTNM N/A
- 52 Week Low
- ILPT $2.45
- CTNM $3.35
- 52 Week High
- ILPT $6.57
- CTNM $20.24
- Technical
- Relative Strength Index (RSI)
- ILPT 38.46
- CTNM 48.88
- Support Level
- ILPT $4.92
- CTNM $10.77
- Resistance Level
- ILPT $6.08
- CTNM $11.34
- Average True Range (ATR)
- ILPT 0.22
- CTNM 0.68
- MACD
- ILPT -0.03
- CTNM -0.15
- Stochastic Oscillator
- ILPT 31.03
- CTNM 31.37
About ILPT Industrial Logistics Properties Trust of Beneficial Interest
Industrial Logistics Properties Trust is a real estate investment trust. It owns and leases industrial and logistics properties throughout the United States. The company's investment portfolio includes industrial lands in Hawaii and industrial and logistics properties in other states. Rental revenue is earned from Hawaii Properties and Mainland Properties.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.